cancer care by Dr bharat Patodiya

🧠 TL;DR Trastuzumab Deruxtecan is a HER2-targeted antibody-drug conjugate (ADC) Combines targeting + chemotherapy in one molecule Used in HER2-positive and HER2-low breast cancer, gastric & some lung cancers Given once every 3 weeks (half-life ~6 days) ❌ NOT the same as trastuzumab (Herceptin) or T-DM1 → common dangerous confusion ⚠️ Major risks: lung toxicity (ILD), heart dysfunction, bone marrow suppression 💰 Cost varies widely → depends on weight, schemes & support programs 👉 Not sure...

🧠 TL;DR Daratumumab is a CD38-targeted immunotherapy used in multiple myeloma and amyloidosis Not every patient needs it immediately-timing is critical Infusion reactions can occur in up to 50% patients initially, but are manageable It interferes with blood tests (Coombs test & protein electrophoresis) Dose does NOT need adjustment in kidney failure or dialysis Cost is typically ₹2–3 lakh/month, but varies due to support programs Many patients consult me to decide whether they truly need...

🧠 TL;DR Nivolumab is a PD-1 immunotherapy that activates your immune system against cancer Used in lung, head & neck, esophagus, melanoma, kidney, lymphoma, colorectal (MSI-high) Long-acting (~26 days) → small delays are usually safe Side effects are immune-related (not infection-related) Timing of side effects gives major diagnostic clues Can be used safely in kidney failure, dialysis, liver dysfunction (non-immune) Cost in India has dropped from ₹4.5 lakh → ~₹1 lakh/month (with generics)...